Predictive Oncology and Renovaro Announce Merger Agreement
Slice of Healthcare Team
Jan 08, 2025
Key Highlights
- Predictive Oncology to merge with Renovaro through a binding letter of intent.
- The deal involves the exchange of preferred stock in Renovaro for Predictive Oncology's shares.
- Merger leverages AI-driven platforms and a vast biobank to accelerate drug discovery.
- Potential for 30% cost savings and enhanced collaboration in cancer research.
- Merger subject to $15 million minimum fundraising and shareholder approval.
Source: Globe Newswire
Notable Quotes
“ Through our discussions with Renovaro, we became increasingly compelled by the strategic potential of combining Predictive’s AI-driven drug discovery platform and vast biobank… ”
Raymond Vennare, Chairman & CEO at Predictive Oncology
“ This transaction with Predictive Oncology furthers our quest to offer cancer patients early diagnosis, a personalized treatment protocol, and recurrence monitoring. ”
David Weinstein, CEO at Renovaro
